{"id":28367,"date":"2024-06-18T15:09:27","date_gmt":"2024-06-18T09:39:27","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28367"},"modified":"2024-06-18T15:09:31","modified_gmt":"2024-06-18T09:39:31","slug":"pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","title":{"rendered":"Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb\u2019s Augtyro FDA Approval; AstraZeneca\u2019s Farxiga FDA Approval"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0725621845e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0725621845e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\/#Takeda_Reveals_Phase_III_Results_for_Soticlestat_TAK-935_in_Dravet_and_Lennox-Gastaut_Syndromes\" >Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\/#Imfinzi_and_Chemotherapy_Combination_Gains_US_Approval_for_Mismatch_Repair_Deficient_Advanced_Endometrial_Cancer\" >Imfinzi and Chemotherapy Combination Gains US Approval for Mismatch Repair Deficient Advanced Endometrial Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\/#Nipocalimab_Shows_Notable_Efficacy_in_Reducing_Sjogrens_Disease_Symptoms_in_Recent_Phase_II_Study\" >Nipocalimab Shows Notable Efficacy in Reducing Sj\u00f6gren\u2019s Disease Symptoms in Recent Phase II Study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\/#FDA_Grants_Approval_for_Augtyro_an_Advanced_Tyrosine_Kinase_Inhibitor_TKI_to_Treat_Patients_with_NTRK-Positive_Advanced_or_Metastatic_Solid_Tumors\" >FDA Grants Approval for Augtyro, an Advanced Tyrosine Kinase Inhibitor (TKI), to Treat Patients with NTRK-Positive Advanced or Metastatic Solid Tumors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\/#FDA_Approves_Farxiga_for_Treating_Type-2_Diabetes_in_Children\" >FDA Approves Farxiga for Treating Type-2 Diabetes in Children<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-takeda-reveals-phase-iii-results-for-soticlestat-tak-935-in-dravet-and-lennox-gastaut-syndromes\"><span class=\"ez-toc-section\" id=\"Takeda_Reveals_Phase_III_Results_for_Soticlestat_TAK-935_in_Dravet_and_Lennox-Gastaut_Syndromes\"><\/span>Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Takeda <\/strong>revealed topline results from its <strong>SKYLINE and SKYWAY studies<\/strong>. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing <strong>soticlestat (TAK-935)<\/strong> plus standard care against placebo plus standard care in <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\">patients with refractory Dravet syndrome<\/a>. Soticlestat narrowly missed the primary endpoint of reducing convulsive seizure frequency from baseline compared to placebo (p-value = 0.06). However, in the six key secondary endpoints, soticlestat demonstrated clinically meaningful and nominally significant outcomes in the responder rate, caregiver and clinician global impression of improvement measures, and seizure intensity and duration scales over the 16-week treatment period (all p-values \u2264 0.008).<\/p>\n\n\n\n<p><strong>SKYWAY (TAK-935-3002)<\/strong> was a multicenter, randomized, double-blind Phase III trial that assessed the effectiveness of soticlestat in combination with standard care versus placebo with standard care in patients with refractory Lennox-Gastaut syndrome (LGS). Soticlestat did not achieve the primary goal of reducing the frequency of Major Motor Drop (MMD) seizures compared to the placebo.<\/p>\n\n\n\n<p>In both the SKYLINE and SKYWAY studies, certain predefined patient subgroups showed statistically significant treatment effects on primary and secondary endpoints, including caregiver and clinician global impressions of improvement, as well as scales measuring seizure intensity and duration over the 16-week treatment period. Further analyses are underway. Soticlestat was generally well tolerated in both studies, exhibiting a safety profile consistent with earlier findings.<\/p>\n\n\n\n<p>Takeda will consult with regulatory authorities to review all data from these studies and decide on the next steps. Additionally, Takeda plans to present the results from both Phase III studies at a forthcoming scientific congress.<\/p>\n\n\n\n<p>Takeda is also evaluating the financial implications of the study results, including potential impairment losses on intangible assets, for the first quarter ending June 30, 2024, and will provide updates as needed promptly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-imfinzi-and-chemotherapy-combination-gains-us-approval-for-mismatch-repair-deficient-advanced-endometrial-cancer\"><span class=\"ez-toc-section\" id=\"Imfinzi_and_Chemotherapy_Combination_Gains_US_Approval_for_Mismatch_Repair_Deficient_Advanced_Endometrial_Cancer\"><\/span>Imfinzi and Chemotherapy Combination Gains US Approval for Mismatch Repair Deficient Advanced Endometrial Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AstraZeneca\u2019s Imfinzi (durvalumab)<\/strong>, when combined with carboplatin and paclitaxel and followed by Imfinzi as a monotherapy, has been approved in the US for treating adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).<\/p>\n\n\n\n<p>The FDA granted approval based on a prespecified exploratory subgroup analysis by MMR status from the DUO-E Phase III trial, with results published in the Journal of Clinical Oncology.<\/p>\n\n\n\n<p>In this trial, the combination of Imfinzi with carboplatin and paclitaxel, followed by Imfinzi alone (Imfinzi arm), reduced the risk of disease progression or death by 58% in patients with dMMR endometrial cancer compared to chemotherapy alone (hazard ratio 0.42; 95% confidence interval 0.22-0.80).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dave Fredrickson, Executive Vice President of the Oncology Business Unit at AstraZeneca, stated: \u201cOver the past few decades, there have been few advancements in <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/endometrial-cancer-market\"><em>endometrial cancer treatment<\/em><\/a><em>, making ongoing innovation essential as the incidence of this cancer is anticipated to increase. The combination of immunotherapy and chemotherapy is becoming a new standard of care in this area, and the approval of Imfinzi provides a significant new treatment option for patients with mismatch repair deficient disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The safety and tolerability profile of the Imfinzi and chemotherapy regimen was generally manageable and consistent with previous clinical trials, showing no new safety concerns.<\/p>\n\n\n\n<p>The combination of Lynparza (olaparib) and Imfinzi, which involved Imfinzi plus chemotherapy followed by maintenance therapy with Imfinzi and Lynparza, also achieved the primary endpoint of progression-free survival (PFS). The trial is ongoing to evaluate overall survival as a key secondary endpoint for both treatment arms. Regulatory applications for the Imfinzi and the combined Imfinzi and Lynparza regimens are currently under review in the EU, Japan, and several other countries based on the DUO-E results.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nipocalimab-shows-notable-efficacy-in-reducing-sjogren-s-disease-symptoms-in-recent-phase-ii-study\"><span class=\"ez-toc-section\" id=\"Nipocalimab_Shows_Notable_Efficacy_in_Reducing_Sjogrens_Disease_Symptoms_in_Recent_Phase_II_Study\"><\/span>Nipocalimab Shows Notable Efficacy in Reducing Sj\u00f6gren\u2019s Disease Symptoms in Recent Phase II Study<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Johnson &amp; Johnson <\/strong>has announced that patients treated with <strong>nipocalimab <\/strong>showed a statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa scores compared to a placebo at 24 weeks, based on baseline measurements. This was the primary endpoint in the Phase 2 DAHLIAS dose-ranging study involving <a href=\"https:\/\/www.delveinsight.com\/report-store\/sjogrens-syndrome-market-size\">adult patients with Sj\u00f6gren\u2019s disease<\/a>. Improvements were seen as early as Week 4 and continued to grow over the 24-week treatment period compared to those receiving the placebo. These findings mark the first positive results for nipocalimab in treating SjD. The study results were highlighted in a late-breaking presentation (LBA0010) and are part of the 30 abstracts Johnson &amp; Johnson is presenting at the <a href=\"https:\/\/www.delveinsight.com\/events\/eular-conference-2024\"><strong>European Alliance of Associations for Rheumatology (EULAR) 2024 Congress<\/strong><\/a>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;These data provide proof of concept for nipocalimab in treating Sj\u00f6gren\u2019s disease and support further clinical development, which is promising news for the approximately four million people worldwide affected by this chronic, debilitating condition,\u201d said Prof. Jacques-Eric Gottenberg, M.D., Ph.D., from the Department of Rheumatology at Strasbourg University Hospital, National Centre for Rare Systemic Autoimmune Diseases, and study investigator. \u201cPatients with Sj\u00f6gren&#8217;s disease need approved advanced therapies to address the serious health consequences of the disease, and I am encouraged by these results and the positive impact on clinically meaningful disease measures.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In addition to reaching the primary endpoint, the group treated with 15 mg\/kg of nipocalimab showed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Clinically significant improvements in secondary endpoints at Week 24, which included assessments of multiple organs (DALc), physician evaluations (PhGAd), and composite tools for clinical trial endpoints (STARe, CRESSf)<\/li>\n\n\n\n<li>Positive trends in key SjD symptoms such as mouth dryness, eye dryness, and vaginal dryness<\/li>\n\n\n\n<li>Safety and tolerability in line with other nipocalimab clinical studies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-grants-approval-for-augtyro-an-advanced-tyrosine-kinase-inhibitor-tki-to-treat-patients-with-ntrk-positive-advanced-or-metastatic-solid-tumors\"><span class=\"ez-toc-section\" id=\"FDA_Grants_Approval_for_Augtyro_an_Advanced_Tyrosine_Kinase_Inhibitor_TKI_to_Treat_Patients_with_NTRK-Positive_Advanced_or_Metastatic_Solid_Tumors\"><\/span>FDA Grants Approval for Augtyro, an Advanced Tyrosine Kinase Inhibitor (TKI), to Treat Patients with NTRK-Positive Advanced or Metastatic Solid Tumors<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bristol Myers Squibb <\/strong>has announced that the FDA has granted accelerated approval for <strong>Augtyro\u2122 (repotrectinib)<\/strong> for treating adults and children aged 12 and older with solid tumors featuring a <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-receptor-tyrosine-kinase-inhibitor-pipeline-insight\">neurotrophic tyrosine receptor kinase (NTRK)<\/a> gene fusion. This approval applies to patients whose tumors are locally advanced or metastatic, or where surgical resection would likely cause severe morbidity, and who have either progressed following treatment or have no satisfactory alternative therapy. The decision is based on the results from the Phase I\/II TRIDENT-1 study, which assessed Augtyro in adult patients with NTRK-positive solid tumors. This indication received accelerated approval based on the overall response rate and duration of response, with continued approval dependent on the verification and description of clinical benefit in confirmatory trials.<\/p>\n\n\n\n<p>The TRIDENT-1 trial enrolled patients with NTRK-positive locally advanced or metastatic solid tumors, encompassing 15 different types of cancer, including both those who had not received prior TKI treatment (n=40) and those who had (n=48). In TKI-na\u00efve patients, after a median follow-up of 17.8 months, 58% (95% CI: 41 to 73) achieved a confirmed objective response rate (cORR). Among these responders, 43% achieved partial responses (PR), and 15% achieved complete responses (CR). The majority (83%) of TKI-na\u00efve responders maintained their response at one year with Augtyro, and the median duration of response (mDOR) had not been reached.<\/p>\n\n\n\n<p>For TKI-pretreated patients, after a median follow-up of 20.1 months, the cORR was 50% (95% CI: 35 to 65), with 50% achieving PR and none achieving CR. Among TKI-pretreated responders, 42% remained in response at one year with Augtyro. The median duration of response (mDOR) was 9.9 months (95% CI: 7.4 to 13.0).<\/p>\n\n\n\n<p>In patients with measurable central nervous system (CNS) metastases at the start of the trial, two out of two TKI-na\u00efve patients and three out of three TKI-pretreated patients showed an intracranial response.<\/p>\n\n\n\n<p>Based on data from clinical trials and how the drug is processed in the body, the recommended dose of Augtyro for pediatric patients aged 12 years and older matches that for adults. This involves taking 160 mg by mouth once daily for 14 days, followed by 160 mg twice daily until the disease either progresses or intolerable side effects occur. The safety and effectiveness of Augtyro have not been confirmed in children under 12 years old who have solid tumors with an NTRK gene fusion. This marks the second approved use of Augtyro in the United States, following its full approval in November 2023 for treating adult patients with locally advanced or metastatic ROS1-positive NSCLC.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-farxiga-for-treating-type-2-diabetes-in-children\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Farxiga_for_Treating_Type-2_Diabetes_in_Children\"><\/span>FDA Approves Farxiga for Treating Type-2 Diabetes in Children<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AstraZeneca&#8217;s Farxiga (dapagliflozin)<\/strong> has received FDA approval for enhancing blood sugar management in children aged 10 years and above who have type-2 diabetes. This decision by the FDA was supported by promising outcomes from the <strong>Phase III T2NOW trial<\/strong> in pediatric patients. Previously, Farxiga was approved in the United States for <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">adults with T2D<\/a> as an additional treatment alongside diet and exercise to improve blood sugar control.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Ruud Dobber, Executive Vice President of AstraZeneca&#8217;s BioPharmaceuticals Business Unit, remarked that the incidence of type-2 diabetes among children and adolescents is increasing. He noted that treatment options in oral form have been scarce for this group. Dobber emphasized that the recent approval is a significant achievement for young patients with type-2 diabetes in the US. He highlighted that this approval expands the potential benefits of the medication to more patients with significant medical needs, underscoring AstraZeneca&#8217;s dedication to advancing innovative treatments in cardiovascular, renal, and metabolic diseases.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Data from the T2NOW Phase III trial, published in The New England Journal of Medicine Evidence, showed that Farxiga led to a significant decrease in A1C levels, which indicate average blood sugar, compared to a placebo. The adjusted average reduction in A1C was -0.62% with Farxiga versus an increase of +0.41% with placebo, resulting in a difference of -1.03% (95% CI: -1.57 to -0.49; p&lt;0.001). These findings were statistically significant for the primary and all secondary endpoints compared to placebo at week 26. The results demonstrate that Farxiga can bring clinically meaningful improvements in blood sugar control for children and adolescents with type 2 diabetes. The safety outcomes in this group were similar to those observed in adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">type 2 diabetes<\/a>, aligning with Farxiga&#8217;s well-established safety profile.<\/p>\n\n\n\n<p>Forxiga has also been authorized for children aged 10 years and older with type 2 diabetes in 56 countries, such as the EU and other areas, following findings from the T2GO Phase III clinical trial. Further regulatory submissions and deployment strategies are being assessed pending additional market evaluations.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against placebo plus standard care in patients with refractory Dravet syndrome. Soticlestat narrowly missed the primary [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28373,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[204,16668,16664,20331,704,349,420,639,5789,17616,2023,19930],"industry":[17225],"therapeutic_areas":[17240,17238,17228],"class_list":["post-28367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight","tag-dravet-syndrome","tag-dravet-syndrome-market","tag-endometrial-cancer","tag-fda","tag-latest-pharma-news","tag-news","tag-pharma-news","tag-recent-pharma-news","tag-sjogren-syndrome","tag-type-2-diabetes","tag-type-2-diabetes-treatment","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Takeda, AstraZeneca, Johnson &amp; Johnson, BMS<\/title>\n<meta name=\"description\" content=\"Takeda\u2019s Soticlestat; AstraZeneca\u2019s Imfinzi and Chemotherapy Combination; Johnson &amp; Johnson\u2019s Nipocalimab; Bristol Myers Squibb\u2019s Augtyro\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Takeda, AstraZeneca, Johnson &amp; Johnson, BMS\" \/>\n<meta property=\"og:description\" content=\"Takeda\u2019s Soticlestat; AstraZeneca\u2019s Imfinzi and Chemotherapy Combination; Johnson &amp; Johnson\u2019s Nipocalimab; Bristol Myers Squibb\u2019s Augtyro\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-18T09:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-18T09:39:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/18150914\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Takeda, AstraZeneca, Johnson & Johnson, BMS","description":"Takeda\u2019s Soticlestat; AstraZeneca\u2019s Imfinzi and Chemotherapy Combination; Johnson & Johnson\u2019s Nipocalimab; Bristol Myers Squibb\u2019s Augtyro","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Takeda, AstraZeneca, Johnson & Johnson, BMS","og_description":"Takeda\u2019s Soticlestat; AstraZeneca\u2019s Imfinzi and Chemotherapy Combination; Johnson & Johnson\u2019s Nipocalimab; Bristol Myers Squibb\u2019s Augtyro","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-06-18T09:39:27+00:00","article_modified_time":"2024-06-18T09:39:31+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/18150914\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","name":"Pharma News | Takeda, AstraZeneca, Johnson & Johnson, BMS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/18150914\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png","datePublished":"2024-06-18T09:39:27+00:00","dateModified":"2024-06-18T09:39:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Takeda\u2019s Soticlestat; AstraZeneca\u2019s Imfinzi and Chemotherapy Combination; Johnson & Johnson\u2019s Nipocalimab; Bristol Myers Squibb\u2019s Augtyro","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/18150914\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/18150914\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png","width":772,"height":482,"caption":"pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/18150914\/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dravet syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dravet syndrome market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">endometrial cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sjogren Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 2 diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 2 Diabetes Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Dravet syndrome<\/span>","<span class=\"advgb-post-tax-term\">Dravet syndrome market<\/span>","<span class=\"advgb-post-tax-term\">endometrial cancer<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sjogren Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Type 2 diabetes<\/span>","<span class=\"advgb-post-tax-term\">Type 2 Diabetes Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 18, 2024","modified":"Updated on Jun 18, 2024"},"absolute_dates_time":{"created":"Posted on Jun 18, 2024 3:09 pm","modified":"Updated on Jun 18, 2024 3:09 pm"},"featured_img_caption":"pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28367"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28367\/revisions"}],"predecessor-version":[{"id":28368,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28367\/revisions\/28368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28373"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28367"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28367"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}